1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Delayed Nasdaq  -  05/19 04:00:00 pm EDT
244.77 USD   +0.33%
05/18AMGEN INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/16AMGEN INC. : Ex-dividend day for
FA
05/13Avantor Names Jonathan Peacock Chairman
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen Declares 2022 First Quarter Dividend, Payable on March 8, 2022

12/03/2021 | 04:00pm EDT

Amgen announced that its Board of Directors declared a $1.94 per share dividend for the first quarter of 2022. The dividend will be paid on March 8, 2022, to all stockholders of record as of the close of business on February 15, 2022. This represents a 10% increase from that paid in each of the previous four quarters.


© S&P Capital IQ 2021
All news about AMGEN INC.
05/18AMGEN INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/16AMGEN INC. : Ex-dividend day for
FA
05/13Avantor Names Jonathan Peacock Chairman
MT
05/12Amgen and lance bass partner to encourage people to do a 'double take' to recognize the..
PR
05/12BridgeBio Inks BBP-398 License With Bristol Myers
DJ
05/11TRANSCRIPT : Amgen Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-202..
CI
05/11INSIDER SELL : Amgen
MT
05/10Pfizer to pay $11.6 bln for Biohaven to tap migraine market
RE
05/10Mizuho Securities Lifts Amgen's Price Target to $208 From $202, Citing Repatha Peak Rev..
MT
05/09Amgen announces webcast of 2022 bank of america healthcare conference
AQ
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2022 26 208 M - -
Net income 2022 6 820 M - -
Net Debt 2022 26 905 M - -
P/E ratio 2022 19,4x
Yield 2022 3,10%
Capitalization 131 B 131 B -
EV / Sales 2022 6,02x
EV / Sales 2023 5,71x
Nbr of Employees 24 200
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 244,77 $
Average target price 246,55 $
Spread / Average Target 0,73%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.8.80%130 756
JOHNSON & JOHNSON2.59%457 706
PFIZER, INC.-14.23%284 192
ABBVIE INC.12.05%268 106
ROCHE HOLDING AG-16.41%265 188
ELI LILLY AND COMPANY3.64%257 689